Cannabis Medicinalis is the Swiss solution for disseminating knowledge about medical cannabis. Through their events and through the collaboration with Copeia, the leading medical cannabis software solution, they support doctors, pharmacists, patients, and producers/manufacturers in the medical cannabis field.
Since August 1, 2022, Switzerland has implemented new legislation, simplifying patient access to medical cannabis and clarifying regulations for production and distribution. This legal change has sparked interest in the medical cannabis industry, potentially positioning Switzerland as a potential hub for international trade, research, and innovation.
Copeia’s digital health applications assist patients and support healthcare providers, including doctors, and other healthcare professionals in prescribing and managing cannabis medications.
Copeia’s platform combines AI-driven software and data-based analysis with expertise from international cannabinoid research and practical knowledge gained through collaboration with doctors, patients, pharmacies, and producers.
Since its founding in 2020, Copeia has been active in the German healthcare market. Copeia’s goal is to expand its digital health applications to other European countries and find partners to achieve this together.
Copeia aims to support patients, doctors, and all relevant stakeholders in the healthcare industry in Switzerland in the therapy with cannabis medications.
In October 2022, Cannabis Medicinalis GmbH organized the Cannabinnoid Conference 2022, which was the 12th IACM Congress and was held in collaboration with the first SGCM Congress. This significant event brought together leading experts, physicians, researchers, and stakeholders from around the world to present and discuss the latest developments and research findings in the field of medical cannabis.